BACKGROUND Digoxin is widely used in patients with atrial fibrillation (AF).
These studies have provided conflicting results, possibly due to varying patient populations and analytical methods (21) (22) (23) (24) (25) (26) (27) .
Digoxin has a narrow therapeutic window, and its levels are markedly influenced by drug-drug interactions and comorbidities (28) . A major limitation of all previous studies examining the safety of digoxin in patients with AF is the lack of serum digoxin concentration measurements necessary to define a possible dose-response relationship. A post hoc analysis of the DIG (Digitalis Investigation Group) trial in 1,171 patients with heart failure but not AF suggested that the serum digoxin concentration was directly related to mortality, with reduced mortality among patients with low digoxin levels (between 0.5 and 0.8 ng/ml) and increased mortality among patients with levels >1.1 ng/ml (29) .
The present study explored the association between digoxin use, serum digoxin concentration, and mortality in patients with AF in the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial (30, 31) .
We analyzed whether this association was modified by the presence of heart failure, serum digoxin concentration, biomarkers, concomitant medications, or any other clinical or laboratory characteristics associated with digoxin use, serum digoxin concentration, and mortality. The efficacy and safety of apixaban versus warfarin were also assessed according to digoxin use.
METHODS
We performed a post hoc digoxin subgroup analysis of the ARISTOTLE trial, which compared apixaban with warfarin for the prevention of stroke or systemic embolism in patients with AF and at least 1 additional risk factor for stroke (30, 31) . The primary efficacy MORTALITY, DIGOXIN USE, AND HEART FAILURE. For this analysis, the primary endpoint was time to all-cause mortality; cardiovascular and noncardiovascular mortality and sudden cardiac death were also analyzed, in which competing causes of death were handled by censoring (30) .
All clinical outcomes were pre-specified in the statistical analysis plan. At each follow-up visit, the use of digoxin was recorded, with start and end dates of use. Patients were classified as taking or not taking digoxin at baseline if they were receiving or not receiving digoxin at the start of the study and as new users if they were not taking digoxin at baseline and started digoxin during the course of the study.
Heart failure was a subgroup of interest and was pre-specified in the statistical analysis plan. It was recorded in the case report form and defined as symptomatic congestive heart failure within The analyses were performed at the Department of Clinical Chemistry, Uppsala University, Uppsala, Sweden, which is accredited according to SS-EN ISO/ IEC 15189, including the interlaboratory external proficiency testing scheme from Equalis AB (Uppsala, Sweden). The levels of the prognostic biomarkers N-terminal pro-B-type natriuretic peptide, troponin I and T, and growth differentiation factor (GDF)-15 were measured in plasma samples by using the Roche or Abbott assays as previously published (32) (33) (34) (35) .
STATISTICAL ANALYSIS. Patients using and those not using digoxin, overall and within the heart failure groups, were compared by using the Fisher exact tests and the Wilcoxon rank sum test for categorical and continuous variables, respectively. Event rates per 100 patient-years of follow-up in patients taking/ not taking digoxin at baseline were computed, and hazard ratios (HRs) with 95% confidence intervals (CIs) comparing event rates between groups were derived. Two different analyses were implemented: a prevalent user analysis and an incident (new) user analysis. Both analyses included mortality endpoints (all-cause, cardiovascular, noncardiovascular, and sudden cardiac death) and hospitalization for heart failure. Table 1 ). Randomized treatment was not associated with prevalent digoxin use and is unlikely to be a relevant confounder; it was therefore not included in the propensity model. Missing values were <1.7% for all variables excluding biomarkers in which missingness was w18%, and were handled by single imputation using the fully conditional specification method (37) . Covariate balance between groups (digoxin and no digoxin) was assessed by using standardized differences (Online Table 2 Sociodemographic and baseline characteristics were fixed covariates whereas concomitant medications, vital signs, laboratory values, and medical history were updated during follow-up (Online Table 3 ). Matching was performed within region, clinical setting where digoxin was initiated (during a heart failure hospitalization, during other hospitalization, or out of hospital), and heart failure status.
Patients starting digoxin out of the hospital were also matched according to time from most recent hospitalization. Covariate balance between matched treated patients and control participants was assessed by using standardized differences (Online Table 4 ). New digoxin users and matched control participants were compared by using a Cox regression with robust sandwich estimate for the covariance matrix. A sensitivity analysis was conducted excluding pairs who were matched during a hospitalization, thus limiting the analysis to out-ofhospital digoxin initiation. In a preliminary analysis, we also evaluated the endpoint of mortality by using marginal structural models for time-varying treatments, and observed similar results. In our study, the Lopes et al.
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M A R C H 1 3 , 2 0 1 8 : 1 0 6 3 -7 4 risk-set matching approach was preferred for transparency and interpretability.
All analyses were performed by using SAS version 9.4 (SAS Institute, Inc., Cary, North Carolina).
RESULTS

POPULATION.
A total of 17,897 patients (98% of the overall population) from ARISTOTLE (30,31) had information available on baseline digoxin use and heart failure status. Of those, 5,824 (32.5%) were taking digoxin at baseline, and 6,693 (37.4%) had concomitant heart failure. A total of 680 (11.7%) patients using digoxin at baseline stopped digoxin before the end of the trial. Median time to stopping was 184 days (25th, 75th percentiles: 50, 366 days). Table 1 Figures 1A and B) .
SERUM DIGOXIN CONCENTRATIONS AND OUTCOMES.
Serum digoxin concentrations at baseline were measured in 4,434 (76.1%) patients taking digoxin.
Baseline characteristics of the patients with and without digoxin concentration data available were similar (Online Table 5 Table 4 ). When endpoint information was added, 2 additional pairs were removed, and the final Kaplan-Meier curves for all-cause death in patients (A) using and not using digoxin at baseline; (B) using or not using digoxin at baseline with and without heart failure (HF); (C) starting digoxin or not among new starters; and (D) starting digoxin or not among new starters with and without HF. CI ¼ confidence interval; HR ¼ hazard ratio.
analysis included 779 patients and 2,337 control participants. Only 1 variable (chronic obstructive pulmonary disease) had standardized differences >10% (11.8%). Baseline characteristics in prevalent and incident cases are described in Online Table 7 .
New digoxin users had significantly higher total mortality (adjusted HR: 1.78; 95% CI: 1.37 to 2.31; p < 0.0001) than matched control participants ( In patients with atrial fibrillation taking digoxin, the risk of death is independently related to digoxin serum concentration. Initiating digoxin is independently associated with higher mortality and sudden death in patients with atrial fibrillation, regardless of heart failure. CI ¼ confidence interval; HF ¼ heart failure; HR ¼ hazard ratio.
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and without heart failure at baseline ( Figures 1C and   1D ). In the sensitivity analysis, similar results were seen in the pairs matched on an outpatient setting only (Online Table 8 ). For all-cause death, the number needed to harm at 1 year was 34 (95% CI: 19 to 84) and at 2 years, it was 17 (95% CI: 9 to 41).
New digoxin use was associated with an increased risk of sudden cardiac death, with a 2-fold higher risk of events in new digoxin users compared with matched control participants (adjusted HR: 2.14; Table 8 ). For sudden cardiac death, the number needed to harm at 1 year was 180 (95% CI: 138 to 1,844) and at 2 years, it was 56 (95% CI: 43 to 568).
New digoxin users had significantly higher rates of hospitalization due to heart failure (adjusted HR:
1.69; 95% CI: 1.15 to 2.49; p ¼ 0.0083) compared with matched control participants ( Table 3 , Online Figure 1 ). These results were similar for patients with heart failure (adjusted HR: 2.06; 95% CI: 1.30 to 3.27; p ¼ 0.0022) but not for patients without heart failure (adjusted HR: 1.22; 95% CI: 0.61 to 2.47; p ¼ 0.58) (Online Figure 2) . Among patients who started digoxin and were hospitalized due to heart failure, the median time to hospitalization was 169 days (25th, 75th percentiles: 52, 326 days). For hospitalization due to heart failure, the number needed to harm at 1 year was 34 (95% CI: 16 to 159) and at 2 years, it was 23 (95% CI: 11 to 106).
APIXABAN VERSUS WARFARIN ACCORDING TO
DIGOXIN USE AT BASELINE. The superiority of apixaban versus warfarin on overall mortality, stroke or systemic embolism, and major bleeding was preserved in digoxin users and nonusers (all p values for interaction >0.05) and consistent with the overall results of the trial (Online Table 9 ).
DISCUSSION
Our study showed that digoxin use at baseline was not independently associated with increased mortality in patients with AF at risk for stroke. However, in patients with AF currently taking digoxin, the risk of death was independently related to serum digoxin concentration and was highest in patients with concentrations $1.2 ng/ml (Central Illustration). There was an independent association between serum digoxin concentration and mortality, with a "doserelated effect" that is consistent with a plausible causal association between digoxin concentrations and risk of death. These observations were strengthened by the finding that, after using a robust risk-set matching approach based on a time-dependent propensity score, the risk of death was greatest early after initiation of digoxin in previous nonusers, particularly with respect to sudden cardiac death. With respect to treated patients, it is not unexpected that incident users experienced more events than prevalent ones. Patients taking digoxin at Abbreviations as in Table 2 . high-sensitivity markers of heart failure strongly suggests that our findings were consistent in patients with and without heart failure.
Despite these limitations, this study was an extensive and comprehensive exploration of the independent association between digoxin concentration and outcomes in the setting of AF. Therefore,
given the lack of evidence of safety from randomized trials, the associations we describe may have a substantial impact on scientific guidelines and the treatment of patients with AF. 
CONCLUSIONS
